Key Findings

⚠️ Psilocybin During Breastfeeding Causes Long-Term Problems

While psilocybin showed promise for pain, another study revealed serious risks for new mothers. Researchers found that psilocybin didn't help stressed mother mice and actually made them more anxious weeks later. Even worse, offspring exposed through breastfeeding developed anhedonia (inability to feel pleasure) in adulthood. The postpartum period appears to change how the brain responds to psychedelics - serotonin receptor activity was reduced in new mothers compared to non-mothers.

💊 Multiple Sclerosis Drug Switches May Be Safer Than Expected

Among 417 MS patients, researchers found that 29% of those taking fingolimod had dangerously low antibody levels (hypogammaglobulinemia), raising infection concerns. However, when these patients switched to rituximab or ocrelizumab (anti-CD20 therapies), their antibody levels actually increased significantly over one year (from 8.0 to 8.6 g/L), and the rate of low antibodies dropped from 29% to 21.5%. This challenges the assumption that switching to these powerful immune-suppressing drugs would make things worse.

🧠 Brain's Internal Clock Controls Depression and Sleep Recovery

Scientists discovered that the molecular clock in brain cells controls how we respond to sleep deprivation's antidepressant effects. When they deleted the core clock gene Bmal1 in specific brain neurons, mice couldn't properly consolidate sleep or benefit from sleep deprivation therapy. Interestingly, sleep deprivation and ketamine (both rapid antidepressants) had opposite effects on clock genes - sleep deprivation increased negative clock genes while ketamine decreased them.

🎯 Long-Acting Antipsychotics Reduce Deaths in Older Adults with Schizophrenia

A large Hong Kong study tracking older adults with schizophrenia found that long-acting injectable antipsychotics significantly reduced both disease relapse and all-cause mortality compared to oral medications. This is particularly important since older patients often struggle with medication adherence due to cognitive decline and complex medication regimens. The injectable formulations provided more consistent drug levels and better outcomes.

📊 Microdosing Psychedelics May Actually Change Health Behaviors

In a naturalistic study of people who chose to microdose psychedelics, researchers found self-reported improvements in various health behaviors. Participants reported changes in areas like exercise, diet, and substance use patterns. However, this was an observational study of people's own choices to microdose, so it's unclear whether the psychedelics directly caused these changes or if motivated people were simply more likely to both microdose and improve their health habits.

🏥 Ketamine Shows Mixed Results for Treatment-Resistant Depression

A retrospective analysis of intravenous racemic ketamine treatment found improvements in global depression severity scores, but the effects varied significantly across individual symptoms. Some patients showed substantial improvement while others had minimal response. The study highlighted the need for better predictors of who will respond to ketamine treatment, as the current approach of trial-and-error can be costly and time-consuming for patients with treatment-resistant depression.